Ranbaxy Laboratories has fully deployed Cegedim Relationship Management’s life sciences compliance solution suite, including AggregateSpend360, in an effort to more efficiently, proactively and successfully respond to the current compounding regulatory environment. Ranbaxy Laboratories Inc., a subsidiary of Ranbaxy Laboratories of India, sells and distributes branded prescription products in the U.S.
 
To satisfy the Sunshine Provisions of the Patient Protection and Affordable Care Act (PPACA), companies are focusing on managing their brands and connecting with targets across pharmacy and prescription channels. AggregateSpend360 is designed to help alleviate time spent meeting the PPACA’s state/federal aggregate spend and disclosure reporting requirements by collecting and centralizing all transfers of value to practitioners, rationalizing the data into one customer view for optimal visibility. The cloud-based solution generates reports specific to each federal/state regulation.
 
The compliance solution suite also includes Cegedim’s Compliance ID to satisfy aggregate spend and disclosure reporting regulations through verified medical licensure information sourced from a database of 12 million registered HCPs and one million healthcare organizations. Ranbaxy is also leveraging Cegedim’s BuzzeoPDMA compliance knowledge through Computer Systems Validation Services, which confirm that systems satisfy both state and federal regulatory standards.
 
“By aligning with Cegedim’s AggregateSpend360 and their compliance suite, we are staying well ahead of the curve regarding new U.S. legislation. Teams across the U.S. enterprise — Primary Care, KOLs, Home Office, IT and Compliance teams — are now empowered with the tools to better track spending, improve data, and ensure that our technology is fully compliant,” said Dr. Ashish Anvekar, senior director of Ranbaxy Laboratories, Inc. “Our company can achieve greater focus in providing patient-centric, quality and value-added pharmaceuticals.”